Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Fulvestrant; Fulvestrant; Letrozole; Megestrol; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- 23 Sep 2016 Planned End Date changed from 1 Feb 2018 to 1 Sep 2018.
- 23 Sep 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Sep 2017.
- 23 Sep 2016 Status changed from recruiting to active, no longer recruiting.